Yazar "Engin, B." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The effect of transcutaneous electrical nerve stimulation in the treatment of lichen simplex: a prospective study(WILEY-BLACKWELL PUBLISHING, INC, 2009) Engin, B.; Tufekci, O.; Yazici, A.; Ozdemir, M.Transcutaneous electrical nerve stimulation (TENS) has recently emerged as a possible effective treatment for pruritic dermatoses. Lichen simplex (LS) is one such condition, which may persist despite intensive topical treatments. To investigate the efficacy of TENS treatment in relieving pruritus in lichen simplex. In total, 22 patients with LS unresponsive to topical corticosteroids underwent TENS treatment. The patients rated the pruritus intensity on a visual analogue scale (VAS). The mean reduction in VAS score from baseline to the end of 4 weeks treatment was 4.50 (95% CI 3.65-5.34) for all patients. The difference between the baseline and at the end of the study was significant (P < 0.01). By the end of the study, 18 (80%) of the subjects experienced a reduction in pruritus intensity of > 50%. From our clinical observation, we suggest that TENS may prove to be a useful and well-tolerated treatment modality for the treatment of pruritus in patients with LS.Öğe The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria(BLACKWELL PUBLISHING, 2008) Engin, B.; Uguz, F.; Yilmaz, E.; Oezdemir, M.; Mevlitoglu, I.Background Chronic idiopathic urticaria (CIU) is associated with severely impaired quality of life (QoL). Objective To determine the levels of depression, anxiety and QoL in CIU patients. Patients and methods This study included 73 patients with CIU, and 34 healthy subjects matched for age and sex were used as controls. The levels of depression, anxiety and QoL were assessed with the Beck Depression Inventory (BDI), the Beck Anxiety Inventory (BAI) and the World Health Organization Quality of Life Assessment-Brief (WHOQOL-BREF), respectively. The reliability and validity of the Turkish versions of these instruments have been examined. Results When compared with healthy controls, patients with CIU had significantly higher BDI and BAI scores and significantly lower physical health and psychological health subscale scores of the WHOQOL-BREF. BDI, BAI and all domains of WHOQOL-BREF were unrelated to age, duration of illness, urticaria activity score (UAS) and visual analogue score (VAS). There was a negative significant correlation between all domains of WHOQOL-BREF and BDI and BAI. Conclusion Our data confirm that QoL is markedly reduced in CIU patients. Physical health and psychological health were found to be the areas QoL most affected in CIU patients. And also we have found that CIU patients frequently suffer from depression and anxiety. The severity of these parameters was found to be positively correlated with the extent of QoL decrease.Öğe Narrow-band ultraviolet B phototherapy for the treatment of vitiligo: evidence against an autoimmune pathogenesis(WILEY-BLACKWELL, 2008) Engin, B.; Baysal, I.; Reisli, I.; Ozdemir, M.; Toy, H.[Abstract not Available]Öğe Patch test results in patients with progressive pigmented purpuric dermatosis(WILEY-BLACKWELL PUBLISHING, INC, 2009) Engin, B.; Ozdemir, M.; Kaplan, M.; Mevlitoglu, I.[Abstract not Available]Öğe Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria(WILEY-BLACKWELL PUBLISHING, INC, 2008) Engin, B.; Ozdemir, M.Background Treatment of chronic idiopathic urticaria (CIU) is difficult. Objective The purpose of this study was to evaluate the efficacy and safety of dapsone in CIU. Methods The response to dapsone was evaluated in 65 CIU patients with a randomized, two armed study: 3-month dapsone + desloratadin and 3-month desloratadin. All were followed for up to 3 months and 3 months after; all took desloratadine 10 mg daily throughout the study. The primary measure of efficacy was a daily urticaria activity score (UAS) of weal numbers and itch (maximum score, 42 per week). Results Sixty-five patients completed the randomized 3-month trial medication. Mean reduction in UAS from baseline at 3 months was 7 [95% confidence interval (95% CI), 6.92-7.08] for active group and 5.77 (95% CI, 5.47-6.08) for control subjects (P < 0.001). The reduction in visual analogue score (VAS) at 3 months for active group (mean, 2.58; 95% CI, 2.33-2.83) and control subjects (mean, 2.55; 95% CI, 2.38-2.73) was also significant (P < 0.001). The reduction of UAS and VAS at 3 months compared between active group and control subjects showed no significant difference. Mean reduction in UAS from the end of the study at 3 months after was 1.16 and -4.8 for active and control subjects, respectively. These results were compared with each other, and it was statistically significant (P <= 0.05). Limitations No placebo was used. The study was not blinded. Lack of blinding may have led to bias. The follow-up period was short. Conclusion This study shows that dapsone leads to a persistent decrease in VAS and UAS and is associated with complete remission in some patients.Öğe Treatment of plaque-type localized scleroderma with retinoic acid and ultraviolet A plus the photosensitizer psoralen: a case series(WILEY, 2008) Oezdemir, M.; Engin, B.; Toy, H.; Mevlitoglu, I.[Abstract not Available]
